China Shineway Pharmaceutical Group Limited (C1S) — Cash Flow-to-Debt Ratio
China Shineway Pharmaceutical Group Limited (C1S) has a Cash Flow-to-Debt Ratio of 0.07x as of June 2023, meaning its operating cash flow of €160.69 Million could theoretically repay 0% of its total liabilities (€2.26 Billion) in one year. Check C1S capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
China Shineway Pharmaceutical Group Limited Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for China Shineway Pharmaceutical Group Limited across 13 annual periods. Also explore China Shineway Pharmaceutical Group Limi balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for China Shineway Pharmaceutical Group Limited (2013–2025)
Year-by-year debt coverage analysis for China Shineway Pharmaceutical Group Limited. For market capitalisation and broader financial context, see market value of China Shineway Pharmaceutical Group Limi.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.43x | €1.17 Billion | €2.72 Billion | ▲ +15.4% |
| 2024 | 0.37x | €963.13 Million | €2.57 Billion | ▲ +1.9% |
| 2023 | 0.37x | €932.63 Million | €2.54 Billion | ▼ -38.8% |
| 2022 | 0.60x | €1.11 Billion | €1.85 Billion | ▲ +11.1% |
| 2021 | 0.54x | €703.15 Million | €1.30 Billion | ▲ +20.0% |
| 2020 | 0.45x | €638.57 Million | €1.42 Billion | ▲ +65.6% |
| 2019 | 0.27x | €368.00 Million | €1.35 Billion | ▼ -50.7% |
| 2018 | 0.55x | €532.59 Million | €966.01 Million | ▼ -5.1% |
| 2017 | 0.58x | €490.65 Million | €844.16 Million | ▼ -33.6% |
| 2016 | 0.87x | €733.53 Million | €838.59 Million | ▲ +0.7% |
| 2015 | 0.87x | €744.71 Million | €857.13 Million | ▲ +14.0% |
| 2014 | 0.76x | €773.16 Million | €1.01 Billion | ▲ +91.9% |
| 2013 | 0.40x | €519.89 Million | €1.31 Billion | — |